Formononetin attenuates corticosterone-induced depressive-like behaviors and neuronal damage via ERα/ERK-CREB-BDNF signaling pathway
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Baoying Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medi…. Hauptthemen laut MEDLINE: Isoflavones, Estrogen Receptor alpha, Depression, Antidepressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Research and Development Project of Henan Province.
Abstract (Originalsprache)
Objectives
Formononetin (FMN) is known for its significant neuroprotective effects, this study aims to investigate the antidepressant potential and underlying mechanisms of FMN. Methods Antidepressant efficacy was evaluated in corticosterone (CORT)-induced depression models. In vivo, CORT-exposed mice received FMN to assess behavioral and hippocampal changes (dendritic spine density, synaptic markers: MAP-2/GAP-43). In silico, network pharmacology and molecular docking predicted FMN’s binding affinity and enriched pathways. In vitro, HT22 cells pretreated with FMN (10 μM, 6 h) were subjected to CORT injury, with mechanistic validation via ERα antagonist (MPP) and ERK inhibitor (PD98059). Key findings FMN alleviated depressive-like behaviors and preserved hippocampal integrity in mice. Bioinformatics analysis revealed FMN’s strong binding to ER subtypes and enrichment in estrogen/MAPK pathways. In vitro, FMN pretreatment activated the ERK-CREB-BDNF axis in CORT-injured HT22 cells, enhancing neuronal survival and synaptic function. The activation was ERα/ERK-dependent, as evidenced by the abolition of protective effects following pharmacological inhibition with MPP (ERα antagonist) or PD98059 (ERK inhibitor). Concomitantly, in vivo FMN treatment restored hippocampal p-ERK/ERK ratios in mice, directly corroborating the ERK-CREB-BDNF pathway activation and highlighting its efficacy in reversing CORT-induced signaling deficits.
Conclusion
FMN exerts antidepressant effects via ERα-mediated neurotrophic signaling (ERK-CREB-BDNF), offering a mechanistic foundation for natural antidepressant development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengdong New District, Zhengzhou 450046,…
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengdong New District, Zhengzhou 450046, P.R. China.
- College of Pharmacy, Henan University of Chinese Medicine, 156 Jinshui East Road, Zhengdong New District, Zhengzhou 450046, P.R. China.
ORCID-Profile: Baoying Wang, Yucheng Li
Förderung
- National Natural Science Foundation of China
- Science and Technology Research and Development Project of Henan Province
Zitieren
APA
Wang, B., Liu, H., Zhang, C., Yan, X., Xu, E., Bai, M., & Li, Y. (2026). Formononetin attenuates corticosterone-induced depressive-like behaviors and neuronal damage via ERα/ERK-CREB-BDNF signaling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag010
Vancouver
Wang B, Liu H, Zhang C, Yan X, Xu E, Bai M, et al. Formononetin attenuates corticosterone-induced depressive-like behaviors and neuronal damage via ERα/ERK-CREB-BDNF signaling pathway. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag010
BibTeX
@article{Wang2026,
author = {Wang, Baoying and Liu, Hui and Zhang, Changjing and Yan, Xiangli and Xu, Erping and Bai, Ming and Li, Yucheng},
title = {Formononetin attenuates corticosterone-induced depressive-like behaviors and neuronal damage via ERα/ERK-CREB-BDNF signaling pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag010}
}
EUVIMED